Global Anti Venom Market to reach USD 1.7 billion by 2027.Global Anti Venom Market is valued approximately at USD 0.97 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 8.54% over the forecast period 2021-2027. Anti-venom (also known as antivenin or anti-venene) is a biological treatment for poisonous bites and stings. The only way to get rid of a venomous bite is to use specialist anti-venoms. Snakes, scorpions, and spiders are among the reptile bites that require the anti-venom vaccine. Anti-venoms for snakes are the most commonly used anti-venoms. There are various factors driving the market growth such as technological advancements and increasing awareness on anti-venoms available. For instance, scientists from the Clodomiro Picado Institute of the University of Costa Rica (ICP-UCR) developed an antidote capable of neutralizing the venom of the black mamba snake (Dendroaspis polylepis), a highly venomous snake of the Elapidae family native to areas of Sub-Saharan Africa. Furthermore, polyvalent anti-venoms are advantageous in areas where a high number of venomous species exist and when it is challenging to produce monovalent antivenoms against all of them. The leading companies in the anti-venom market are focusing on creating polyvalent anti-venoms due to the multiple benefits. For example, the University of Arizona released a polyvalent F(ab)2 Equine, an anti-venom approved for the treatment of the North American coral snake (Micrurus) bite in 2019. However, lack of regulatory capacity for the control of anti-venoms in countries , may impede market growth over the forecast period of 2021-2027.

Geographically, Asia Pacific is dominating the market growth of Anti venom market, factors supporting towards the growth are high frequency of snake bites and other poisonous bites in countries such as Bangladesh and India. For example, the Journal of the Association of Physicians of India reported in 2017 that 50,000 people die in India each year as a result of venomous snake bites.

Major market player included in this report are:

Boston Scientific Corporation
Bharat Serums and Vaccines Ltd
Merck & Co. Inc.
Rare Disease Therapeutics Inc.
Boehringer Ingelheim International GmbH
Flynn Pharma Ltd
Merck KGaA
CSL Limited
Pfizer Inc.
Micropharm Limited



The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Species:
Snake
Scorpion
Spiders
Other Species
By Anti Venom type:
Polyvalent Anti-venoms
Monovalent Anti-venom
Other Anti-venom Types
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Anti Venom Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors